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Purpose: The aims of this article were to character-
ize the patterns of treating rheumatoid arthritis with
biologics and to evaluate costs using claims data from
the Japan Medical Data Center Co, Ltd.
Methods: Patients aged 16 to o75 years who were
diagnosed with rheumatoid arthritis and prescribed
adalimumab (ADA), etanercept (ETN), inﬂiximab
(IFX), tocilizumab (TCZ), abatacept, certolizumab,
or golimumab between January 2005 and August
2014 were included. For the cross-sectional analysis,
the annual costs of ETN, IFX, ADA, and TCZ from
2009 to 2013 were assessed. For the longitudinal
analysis, patients prescribed these biologics as the ﬁrst
line of biologics, from January 2005 to August 2014,
were included. The cost of biologic treatment over 1,
2, and 3 years (including prescription of subsequent
biologics) and direct medical costs (including treat-
ment of comorbidities) were compared between
groups. Discontinuation and switching rates in each
group were estimated, and multivariate analyses were
conducted to estimate an adjusted hazard ratio of
discontinuation and switching rates among each
group. The dose of each ﬁrst-line biologic treatment*Current afﬁliation: Department of Rheumatology and Clinical
Immunology, Wakayama Medical University, Wakayama,
Japan.
June 2016until discontinuation was analyzed to calculate rela-
tive dose intensity.
Findings: The cross-sectional annual biologic costs
of ETN, IFX, ADA, and TCZ were $8000 (2009
and 2013), $13,000 (2009) and $15,000 (2013),
$10,000 (2009) and $11,000 (2013), and $9000
(2009) and $8000 (2013), respectively. In longitudinal
analyses (n ¼ 764), 276 (36%) initiated ETN; 242
(32%), IFX; 147 (19%), ADA; and 99 (13%), TCZ.
The 1-year cumulative annual biologic costs per
patient from the initial prescription of ETN, IFX,
ADA, and TCZ as the ﬁrst-line biologic treatment
were $11,000, $19,000, $16,000, and $12,000.
The corresponding direct medical costs over 1 year
from the initial prescription were $17,000, $26,000,
$22,000, and $22,000. Costs remained greatest in the
IFX-initiation group at year 3. The discontinuation
rates at 36 months with ETN, IFX, ADA, and TCZ
were 37.7%, 52.3%, 55.8%, and 39.5%; the switch-
ing rates were 12.5%, 27.1%, 31.0%, and 16.7%.
The mean (95% CI) relative dose intensities until
discontinuation of ETN 25 mg, ETN 50 mg,
IFX, ADA, and TCZ were 1.02 (0.95–1.10), 0.82Accepted for publication March 14, 2016.
http://dx.doi.org/10.1016/j.clinthera.2016.03.022
0149-2918/$ - see front matter
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Clinical Therapeutics(0.79–0.85), 1.16 (1.12–1.20), 0.95 (0.90–0.99), and
0.96 (0.93–1.00).
Implications: Considered costs and discontinuation
and switching event rates were lowest with ETN
versus IFX, ADA, or TCZ used as the ﬁrst-line
biologic. Despite limitations, these ﬁndings imply
clinical cost-reductive beneﬁts of ETN as the ﬁrst-
line biologic treatment option for rheumatoid arthritis
in Japan. (Clin Ther. 2016;38:1359–1375) & 2016
Elsevier HS Journals, Inc. All rights reserved.
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rheumatoid arthritis.INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inﬂammatory
autoimmune disease characterized by joint pain and
stiffness, followed by progressive joint destruction and
disability. In addition to physical impairment and a
shortened life expectancy, RA can result in substantial
socioeconomic costs.1,2 The prevalence of RA in Japan
is estimated to be between 0.6% and 1.0%,3 which is
comparable to that in other parts of the world.4
Thus, the socioeconomic impact of RA cannot be
overlooked.
Despite the debilitating nature of RA, several
biologic immunotherapies have been approved for
inhibiting the progression of structural damage
and for improving physical function in patients
with moderate to severe disease.5 For over a decade,
biologics—including the tumor necrosis factor (TNF)-
α inhibitors etanercept (ETN; approved by the
Pharmaceuticals and Medical Devices Agency
[PMDA] in Japan in 2005 and by the US Food and
Drug Administration [FDA] in 1998), inﬂiximab (IFX;
PMDA, 2003; FDA, 1999), and adalimumab (ADA;
PMDA, 2008; FDA, 2002)—have been used for
treating RA in global markets including Japan. The
interleukin-6 inhibitor tocilizumab (TCZ) was ﬁrst
approved by the PMDA in 2008, followed by the FDA
in 2010. The cluster of differentiation 80/86 inhibitor
abatacept was approved by the PMDA in 2010 and by
the FDA in 2005. The TNF inhibitors certolizumab
pegol and golimumab were approved by the PMDA
in 2012 and 2011, respectively, and by the FDA in
2009. To date, few head-to-head randomized clinical
trials have assessed the comparative effectiveness
of these biologics in the treatment of RA, but1360those few have generally demonstrated comparable
efﬁcacy.6–12
The treatment of RA is required long term, which
creates a signiﬁcant clinical and economic burden for
patients and payers. The cost of RA varies widely
between countries,13 partly because of the varying use
of biologic treatments, which are substantially more
costly than are conventional synthetic disease-modifying
antirheumatic drugs.14–16 The market for developing
original biologics for the treatment of RA is saturated,
and cost considerations by rheumatologists are becom-
ing more important, especially as biosimilar biologics
become more available.17 The impact of drug costs on
direct medical expenditures is also a cause for concern
owing to the widespread use of biologics for the
treatment of RA. However, a recent study from
Germany showed that improvements in functional
status and reductions in health care resource utiliza-
tion as a result of biologic use have largely offset the
increased drug costs.18
Accumulating data from global registries19–21 and
from Japanese cohorts22 suggest that continuance rates
differ among biologic treatments for RA, even between
members of the same drug class. The main reasons
for discontinuations are lack of efﬁcacy and adverse
events (AEs). Poor adherence to medications
can reduce effectiveness and increase the utilization
of health care services, thereby increasing overall
costs.23,24
Current RA treatment practices in Japan are
poorly documented,3 and the impact of biologic
use on costs is unknown. The aim of this study was
therefore to characterize the patterns of treating
RA with biologics and to evaluate the direct costs
of biologics and medical costs using claims data
from Japan.MATERIALS AND METHODS
Data Source
This retrospective analysis utilized reimbursement
data from the Japan Medical Data Center Co, Ltd
(JMDC). Data were received from the JMDC on
February 4, 2015. The JMDC, in collaboration with
multiple health insurance societies, has accumulated
inpatient, outpatient, and pharmacy claims data
from approximately 2.8 million insured members
cumulatively from 2005 to 2014. Claims data con-
tained within this database are nationwide and areVolume 38 Number 6
N. Sugiyama et al.representative of RA-related prescriptions from rheu-
matologists and general practitioners.
Patient Population
Two types of analyses were conducted in this study;
cross sectional and longitudinal. The study design is
depicted in Figure 1. In the cross-sectional analysis,
patients diagnosed with RA by a code from the
International Classiﬁcation of Diseases, Tenth
Revision (M058, M059, M060, M068, or M069)
and who were prescribed ETN, IFX, ADA, TCZ,
abatacept, certolizumab, or golimumab between
January 2005 and August 2014 were included in this
study. For cross-sectional annual cost analysis, 2014
data were excluded because there were o12 months
in the 2014 study period. In longitudinal analysis,
only patients who had been prescribed ETN, IFX,
ADA, or TCZ as the ﬁrst-line biologic (deﬁned as the
ﬁrst prescription of a biologic in the JMDC databaseCross-sectional cumulative share analysis: N = 1,754
Patients diagnosed with RA by an ICD10 code: M058, M059, M060,
M068, M069 who were prescribed ETN, IFX, ADA, TCZ, abatacept,
certolizumab, and golimumab between January 2005 and August 2014
Cross-sectional annual cost analysis: N = 
Between January 2009 and December 2
Longitudinal analysis: N = 764
ETN 50mg/week: n = 16
ETN 50mg/week: n = 16
ETN 25mg/week: n = 108
ETN 25mg/week: n = 101
ADA: n = 147IFX: n = 242
IFX: n = 217
TCZ: n = 85
TCZ: n = 99
RDI analysis: N = 697
ADA: n = 130
Patients who have been prescribed ETN, IFX, ADA, TCZ 
as first-line biologics.
N = 1,592
N = 826
N = 821
Patients who have not been prescribed biologics
in the preceding 3 months:
Patients who are aged 16 to <75 years
at the initial prescription of biologics:
Inclusion Criteria
Figure 1. Study design. Patients diagnosed with rheuma
cumulative share analysis, a cross-sectional
relative dose intensity (RDI) analysis, accord
ADA ¼ adalimumab; ETN ¼ etanercept; IC
Revision; IFX ¼ infliximab; RDI ¼ relative dose
June 2016between April 2005 and August 2014 after a 3-month
period during which no biologic prescriptions were
made) and who were aged 16 to o75 years at the
ﬁrst prescription of a biologic were included. Due
to the small numbers of patients receiving ETN 10 mg
(o17.5 mg/wk) or abatacept, certolizumab, or
golimumab (o50 patients per drug), data from these
patients were not included in the analysis.
Codes from the International Classiﬁcation of
Diseases, Tenth Revision and Anatomical Therapeutic
Chemical were used for identifying patients' concur-
rent medications and comorbidities. The analysis
included data from only deidentiﬁed patients, and as
such, institutional review board approval and patient
consent were not required.
Statistical Analysis
Descriptive statistics (mean [SD]) were used
for summarizing patients' demographic and disease1,612
013
8
4
Cross-sectional cumulative share analysis
Cross-sectional annual cost analysis
Exclusion Criteria
>1 biologics at initial prescription
month
Patients who received
ETN 10 mg/week
1-, 2-, and 3-year cumulative cost analysis
Discontinuation rate and switching rate analysis
Exclusion Criteria
Follow-up period <3 months
Doses at Months 2 and 3 were 0
RDI analysis
toid arthritis (RA) were included in a cross-sectional
annual cost analysis, longitudinal analysis, and
ing to the inclusion and exclusion criteria shown.
D-10 ¼ International Classification of Diseases, Tenth
intensity; TCZ ¼ tocilizumab.
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Clinical Therapeuticscharacteristics in the month of biologic initiation;
continuous parameters were analyzed with 1-way
ANOVA; categorical parameters, by χ2 tests. If a
statistically signiﬁcant difference was found, a multi-
ple comparison test was conducted using a Tukey test
for continuous parameters and adjusted χ2 test by the
Bonferroni method for categorical parameters. SPSS
version 18 (SPSS Inc, Chicago, Illinois, USA) was used
for all analyses.
The cross-sectional cumulative share of each bio-
logic (ETN, IFX, ADA, TCZ, abatacept, certolizumab,
and golimumab) prescribed from 2005 to 2014 was
calculated. The cross-sectional annual cost of ETN,
IFX, ADA, TCZ, and a mean of all biologics (includ-
ing abatacept, certolizumab, and golimumab) per
patient, were also assessed from 2009 to 2013 based
on actual prescribing and corresponding US National
Institutes of Health drug price. If biologic use spanned
several years, costs were calculated from the initial
claim month from the JMDC database to December of
that year, then yearly (from January) thereafter.
Annual data on the costs of ADA and TCZ were
not available or were very limited between 2005 and
2008; this time period was therefore excluded from
the cross-sectional cost analysis.
The 1-, 2-, and 3-year cumulative biologic-related
and direct medical costs in patients with a 41-, 42-,
or 43-year follow-up period, respectively, were com-
pared between each treatment group after the initial
prescription of biologics to biologic-naive patients (see
Supplemental Figure in the online version at http://dx.doi.
org/10.1016/j.clinthera.2016.03.022). Biologic-related
costs included prescribing of Z2 biologics after a
switch, and direct medical costs included the costs of
treating comorbidities. Costs (including patients' copay-
ments) in Japanese yen were converted to US dollars
(1¥ ¼ $0.01). The differences in direct medical costs
between treatment groups over 3 years were analyzed
by Steel-Dwass tests (conducted using the statistical
software package R version 2.15.0, R Foundation for
Statistical Computing, Vienna, Austria).
Month-36 rates of discontinuing and switching to
other biologics (after the initial prescribing of bio-
logics to biologic-naive patients) were estimated using
Kaplan-Meier survival analysis. An event was consid-
ered a discontinuation if the drug was prescribed for
an administration interval not longer than can be
explained by the dosing schedule for each biologic
(ETN, 4 months; IFX, 5 months; ADA, 4 months; and1362TCZ, 4 months) or when one biologic was switched to
another. Data were censored if a patient was withdrawn
from the JMDC or was coming to the end of the
observation period. Exploratory analysis of pairwise
comparisons of discontinuation rates between treatment
groups were by log-rank (Mantel-Cox) tests. If there
were signiﬁcant differences in baseline demographic and
disease characteristics between treatment groups, multi-
variate analyses with these baseline variables using a
Cox proportional hazards model were conducted to
estimate adjusted hazard ratios (HRs) of discontinuation
and switching rates among each group.
The dose of each biologic after initial prescribing
to biologic-naive patients until discontinuation or
switching to another biologic was analyzed to calcu-
late relative dose intensity (RDI), calculated as (Actual
cumulative dose)/(Initial dose  Period until discontin-
uation). The initial dose was estimated from the
dose information from months 1, 2, and 3. ETN
is prescribed weekly, whereas ADA is prescribed
biweekly; therefore, the dose at month 1 was excluded
(to avoid underestimation of dose in the case of a
patient initiating the treatment from the end of the
month), and the mean doses of ETN and ADA at
months 2 and 3 were used for calculating the initial
dose per month. If the doses at months 2 and 3 were
zero, then the data from those patients were excluded
from the analysis owing to difﬁculties in estimating the
initial dose accurately. Because TCZ is prescribed
monthly, the median doses of TCZ at months 1, 2,
and 3 were used for calculating the initial dose per
month. IFX has a 1- to 2-month titration phase and a
maintenance phase at monthZ3; therefore, the actual
dose at month 1 to 2 and the estimated maintenance
dose for month Z3 were separately calculated and
added to the denominator. The dose at month 3 (or
the ﬁrst month thereafter when the dose was not zero)
was used as the initial dose of the maintenance phase.
The data from patients with a follow-up of o3
months were excluded from the analysis, so popula-
tion sizes in the RDI analysis may be smaller than the
overall population size. In the RDI analysis, patients
receiving a mean dose of ETN of 17.5 to 37.5 mg/wk
or 437.5 mg/wk between months 2 and 3 were
assigned to the ETN 25 or 50 mg dose group,
respectively. If a patient was identiﬁed as a censored
case when he/she withdrew from the JMDC or was
coming to the end of the observation period before
biologic discontinuation or switching, the period untilVolume 38 Number 6
N. Sugiyama et al.discontinuation in the denominator of the RDI equa-
tion was deﬁned to be continued until the censored
month.
In Japan, the approved dose of ETN is 10 to 25 mg
twice per week, or 25 to 50 mg once per week; for
IFX, the initial dose is 3 mg/kg at 0, 2, and 6 weeks,
and 3 to 10 mg/kg every 8 weeks orr6 mg/kg every 4
to 8 weeks; for ADA, the dose is 40 to 80 mg every 2
weeks; and for TCZ, the dose is 8 mg/kg every
4 weeks.
In the analyses of cumulative costs, discontinuation
rate, switching rate, and RDI, the initial prescribing of
a biologic to a biologic-naive patient aged 16 to o75
years was deﬁned as the ﬁrst prescribing of a biologic
after a 3-month period during which no biologic
prescriptions were made.RESULTS
A total of 1754 patients were identiﬁed for the cross-
sectional analysis of cumulative share of biologics
between January 2005 and August 2014 (Figure 1).
Of these patients, data from 1612 were included in the
annual cost analysis, conducted between January
2009 and December 2013. A total of 764 patients
were identiﬁed for the longitudinal analysis of 1-, 2-,
and 3-year cumulative costs and an analysis of
discontinuation and switching rates. Data from a
subset of these patients (n ¼ 697) were also included
in the RDI analysis.2005 2006 2007 2008 2009 2010
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Figure 2. Share of biologics prescribed per year. Data
prescribed between 2005 and 2014. *Data fr
June 2016Cross-Sectional Cumulative Share and Cost
Analysis
The proportion of patients receiving each biologic
varied from 2005 to 2014 (Figure 2). In 2013, 37% of
patients were receiving ETN; 20%, IFX; 13%,
ADA; and 16%, TCZ. The proportion of patients
receiving abatacept was 6%; certolizumab, 1%; and
golimumab, 6%. Data from 2014 represent the ﬁrst
half of the year only.
The cross-sectional cost of ETN per patient per
year was $8000 from 2009 to 2013 (Figure 3). The
mean cost of IFX increased over the observation
period, from $13,000 in 2009 to $15,000 in
2013. The approved maximum dose of IFX changed
in 2009 (from 3 mg/kg every 8 weeks to 10 mg/kg
every 8 weeks or r6 mg/kg every 4–8 weeks),
accounting for some of this increase. The cost of
ADA per patient per year was $10,000 to $11,000
from 2009 to 2013. The cost of TCZ increased from
$9000 in 2009 to $11,000 in 2011 and then
decreased to $8000 in 2012 and 2013, owing to a
25% reduction in price in 2012, per the National
Institutes of Health.
Longitudinal Analysis
Patients’ Demographic and Characteristics
Of the 764 patients included in the longitudinal
analysis, 36% (n ¼ 276) initiated ETN; 32%
(n ¼ 242), IFX; 19% (n ¼ 147), ADA; and 13%
(n ¼ 99), TCZ (Figure 1). Age distribution and the2011 2012 2013 2014*
Etanercept
Infliximab
Adalimumab
Golimumab
Tocilizumab
Abatacept
Certolizumab
represent the cumulative proportion of biologics
om 2014 represent quarters 1 and 2.
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Figure 3. Annual cost of biologics per patient. Data are given as mean US $ (1 yen ¼ $0.01).
Clinical Therapeuticsprevalence of comorbidities were generally similar
across treatment groups (Table I). There were more
males in the IFX and ADA groups than in the ETN
and TCZ groups (P ¼ 0.014), and the methotrexate
dose, in milligrams per week per person, at biologic
initiation was greater in those receiving ADA than in
the other treatment groups (P ¼ 0.039).
Longitudinal 1-, 2-, and 3-Year Cumulative Cost
Analysis
The 1-year cumulative ﬁrst-line biologic costs per
patient per year from the initial prescription of ETN,
IFX, ADA, and TCZ were $11,000, $19,000,
$16,000, and $12,000, respectively (Figure 4A).
After 1, 2, and 3 years, the cost of the biologic was
signiﬁcantly less when ETN was prescribed as the
ﬁrst-line biologic treatment versus when ADA or IFX
was prescribed (both, P o 0.01). The cost of the
biologic was also signiﬁcantly greater when IFX or
ADA was prescribed ﬁrst versus TCZ after 1 and 2
years (all, P o 0.001). After 3 years, IFX remained
signiﬁcantly more costly than TCZ if prescribed ﬁrst
(P o 0.05), but the cost of ADA as the ﬁrst-
line biologic treatment was no longer signiﬁcantly
greater than that of TCZ. Across all 3 years, the
costs of the biologics in those initially prescribed
ETN were comparable to that in those initially
prescribed TCZ.
The cumulative direct medical costs of the initial
prescribing of ETN, IFX, ADA, and TCZ were
$17,000, $26,000, $22,000, and $22,000, respec-
tively, in 1 year and $46,000, $65,000, $60,000, and1364$49,000 in 3 years (Figure 4B). These costs represent
not only RA-related costs but also the total costs
accepted by the health insurance societies. Some
common comorbidities and their contributions to
these costs are shown in Table II. Over all 3 years,
direct medical costs were signiﬁcantly less when ETN was
prescribed as the ﬁrst-line biologic compared with IFX
(all years, P¼ 0.001) and ADA (all years, Po 0.05). The
direct medical costs in year 1 were also less in those
prescribed ETN versus TCZ (P ¼ 0.008) and ADA
versus IFX (Po 0.05) as the ﬁrst-line biologic treatment.
Direct medical costs were less over 1 and 2 years
in patients prescribed TCZ ﬁrst versus IFX ﬁrst
(P r 0.001). TCZ was associated with signiﬁcantly
lesser total costs than was ADA after 2 years only
(P o 0.05).
Overall, the costs of concurrent medications in-
creased from 1 year to 3 years in all of the groups. but
there were no signiﬁcant differences between groups
(Table II). Self-injection and outpatient chemotherapy
management fees were greatest in the ETN group in 1
year versus IFX and ADA (both, P o 0.01), 2 years
versus ADA (P o 0.05), and 3 years versus ADA and
IFX (both, Po 0.05). In 1 year, medical practice costs
were greatest with TCZ versus ETN and IFX (both,
Po 0.001) and with ADA versus ETN and IFX (both,
P o 0.05). Signiﬁcant differences in medical practice
costs were not seen at 2 and 3 years.
Discontinuation and Switching Rate Analysis
The discontinuation rates (95% CI) at 36 months
for the TNF inhibitors ETN, IFX, ADA, and TCZ asVolume 38 Number 6
Table I. Baseline demographic and clinical characteristics of the patients at treatment initiation.
Characteristic
ETN
(n ¼ 276)
IFX
(n ¼ 242)
ADA
(n ¼147)
TCZ
(n ¼ 99) P*
Age
Group, no. (%)
Z16–o30 y 14 (5.1) 21 (8.7) 14 (9.5) 7 (7.1) 1.000
30–o40 y 64 (23.2) 38 (15.7) 31 (21.1) 13 (13.1) 0.236
40–o50 y 75 (27.2) 77 (31.8) 39 (26.5) 24 (24.2) 1.000
50–o60 y 74 (26.8) 72 (29.8) 37 (25.2) 27 (27.3) 1.000
60–o75 y 49 (17.8) 34 (14.0) 26 (17.7) 28 (28.3) 0.085
Mean (SD), y 47.5 (11.9) 46.9 (11.5) 46.9 (12.4) 50.9 (13.0) 0.036a
Male, no. (%) 54 (19.6) 72 (29.8) 35 (23.8) 13 (13.1) 0.014b
Oral corticosteroid dose,† mean (SD),
mg/d
6.0 (4.6) 5.8 (4.4) 5.5 (3.6) 7.7 (8.6) 0.427
Methotrexate dose,‡ mean (SD),
mg/wk
8.1 (2.8) 8.4 (3.1) 9.3 (3.5) 8.4 (3.2) 0.039c
Comorbidity§, no. (%)
Renal failure 5 (1.8) 7 (2.9) 2 (1.4) 3 (3.0) 1.000
Interstitial pneumonia 8 (2.9) 12 (5.0) 7 (4.8) 8 (8.1) 1.000
COPD 2 (0.7) 1 (0.4) 1 (0.7) 2 (2.0) 0.138
Peptic ulcer 43 (15.6) 38 (15.7) 31 (21.1) 19 (19.2) 1.000
Chronic liver disease 10 (3.6) 6 (2.5) 9 (6.1) 9 (9.1) 1.000
Depression 83 (30.1) 67 (27.7) 46 (31.3) 39 (39.4) 1.000
Osteoporosis 7 (2.5) 5 (2.1) 5 (3.4) 5 (5.1) 0.807
Diabetes 72 (26.1) 61 (25.2) 38 (25.9) 26 (26.3) 0.797
None 128 (46.4) 107 (44.2) 64 (43.5) 37 (37.4) 1.000
ADA ¼ adalimumab; COPD ¼ chronic obstructive pulmonary disease; ETN ¼ etanercept; IFX ¼ inﬂiximab; TCZ ¼
tocilizumab.
In multiple comparison tests:
aP ¼ 0.030 for IFX vs TCZ.
bP ¼ 0.029 for ETN vs IFX and P ¼ 0.005 for IFX versus TCZ.
cP ¼ 0.022 ETN vs ADA.
*ANOVA was used for continuous variables; χ2 was used for categorical variables.
†Converted to prednisolone dose. Patients who were prescribed oral corticosteroid without sufﬁcient information for
prednisolone conversion were excluded from the calculation of oral corticosteroid dose. Patients included: ETN, n ¼ 129;
IFX, n ¼ 86; ADA, n ¼ 59; TCZ, n ¼ 47.
‡Weekly methotrexate dose at the same month as biologic initiation was calculated using only dispensing claims due to
missing prescription date information from inpatient/outpatient claims.
§Comorbidities at biologic initiation were identiﬁed by International Classiﬁcation of Diseases, Tenth Revision (ICD-10) codes and/
or by drug prescriptions (Anatomic Therapeutic Chemical [ATC] codes), or extracted using standard Japanese disease
terms: renal failure, ICD-10 N18 or N19; interstitial pneumonia, standard disease term in Japan ; COPD, ICD-
10 J42, J43, J44; peptic ulcer, ICD-10 K25, K26, K27; chronic liver disease; ICD-10 K74, K73; depression, ICD-10 F32;
osteoporosis, ICD-10 M80, M81, M82; diabetes, E10, E11, E13, E14 with ATC code A10.
N. Sugiyama et al.the ﬁrst-line biologic treatments were 37.7% (30.5–
44.9), 52.3% (44.7–59.9), 55.8% (43.0–68.6), and
39.5% (25.3–53.6), respectively (Figure 5A). From theJune 2016long-rank test, the unadjusted discontinuation rate
was less with ETN as the ﬁrst-line biologic compared
with ADA and IFX (P ¼ 0.014 and P ¼ 0.004,1365
Etanercept (ETN)
Infliximab (IFX)
Adalmumab (ADA)
Tocilizumab (TCZ)
1 2 3
0
20,000
40,000
60,000
80,000
First biologic presribed:
18,223
32,119
40,489
16,931±
±
±
±
±
±
±
±
±
±
±
±
21,539
47,754
30,673
11,033
13,665
22,8129,107
30,546
13,991
34,038
8,812
21,096
4,724
12,426
16,477
3,884
6,560
18,611
11,468
4,453
M
ea
n 
(S
D
) 
co
st
 o
f 
bi
ol
og
ic
s 
($
)
ETN versus IFX
ETN versus ADA
ETN versus TCZ
ADA versus IFX
ADA versus TCZ
IFX versus TCZ
P < 0.001
P < 0.001
P = 0.467
P = 0.853
P < 0.001
P < 0.001
Years
P < 0.001
P < 0.001
P = 0.657
P = 0.949
P < 0.001
P < 0.001
P < 0.001
P = 0.003
P = 0.951
P = 0.544
P = 0.184
P = 0.021
100,000
80,000
60,000
40,000
20,000
0
1 2 3
17,355
25,760
8,325±
9,661±
±
±
±
±
± ±
±
±
±
±
21,878
6,250
22,453
13,690
30,929
12,399
46,080
17,50242,368
13,850
36,059
20,612
45,778
18,598
65,479
27,062
59,598
22,597
48,822
21,211
Etanerecpt (ETN)
Infliximab (IFX)
Adalimumab (ADA)
Tocilizumab (TCZ)
ETN versus IFX
ETN versus ADA
ETN versus TCZ
ADA versus IFX
ADA versus TCZ
IFX versus TCZ
P < 0.001
P < 0.001
P = 0.008
P = 0.019
P = 0.143
P < 0.001
Years
P < 0.001
P = 0.012
P = 0.944
P = 0.817
P = 0.430
P = 0.061
P < 0.001
P < 0.001
P = 0.517
P = 0.745
P = 0.010
P = 0.001
First biologic presribed:
M
ea
n 
(S
D
) 
m
ed
ic
al
 c
os
t 
($
)
A
B
Figure 4. Cumulative biologic costs (A) and direct medical costs (B) incurred over 3 years after the initial
prescription. Direct medical costs include cost of treatments for comorbidities. Data are given as
mean (SD) US $ (1 yen ¼ $0.01). P values obtained by Steel-Dwass test.
Clinical Therapeuticsrespectively) but did not largely differ between ADA,
IFX, and TCZ (Figure 5A). Mean (95% CI) survival
times (in months) with ETN, IFX, ADA, and TCZ
were 28.1 (26.5–29.6), 24.5 (22.7–26.3), 24.4 (21.9–
26.8), and 26.9 (24.0–29.9) (Figure 5A). Survival time
was signiﬁcantly longer with ETN versus ADA and
IFX (both, Po 0.05). Because the distribution of age,
sex, and methotrexate dose signiﬁcantly differed1366between treatment groups, multivariate analyses with
these baseline variables using a Cox proportional
hazards model was conducted to estimate an
adjusted HR of the discontinuation rate in each
group. The adjusted HRs (95% CI) versus ETN
(reference) were signiﬁcantly greater for ADA and
IFX (1.618 [1.132–2.313] and 1.534 [1.138–2.068])
(Table III).Volume 38 Number 6
Table II. Cost of concurrent medications and rheumatoid arthritis treatment-related costs. Data are given as
mean (SD) US $ (1¥ = $0.01).
Item ETN (n ¼ 276) IFX (n ¼ 242) ADA (n ¼ 147) TCZ (n ¼ 99)
csDMARDs*
1 y 748 (1042) 686 (840) 856 (1219) 868 (1483)
2 y 1478 (2098) 1417 (1858) 1558 (1534) 1703 (2721)
3 y 2404 (3463) 1955 (2186) 2392 (2761) 1986 (2424)
Oral corticosteroids†
Year 1 30 (41) 27 (40) 26 (36) 35 (54)
Year 2 47 (69) 50 (77) 46 (72) 68 (109)
Year 3 64 (100) 64 (100) 64 (110) 92 (155)
NSAIDs‡
Year 1 172 (271) 190 (253) 190 (235) 194 (264)
Year 2 300 (453) 314 (391) 408 (492) 306 (466)
Year 3 423 (618) 396 (459) 603 (648) 438 (632)
Self-injection management fee/outpatient chemotherapy premium
Year 1 352 (363)a, b 205 (188) 206 (287) 325 (334)
Year 2 666 (713)c 370 (336) 412 (532) 508 (576)
Year 3 1013 (1029)c, d 506 (455) 425 (676) 736 (874)
Medical practice cost§
Year 1 224 (118)c, e 215 (110)f, g 252 (115) 314 (256)
Year 2 413 (238) 414 (217) 459 (204) 506 (293)
Year 3 625 (332) 573 (307) 691 (302) 783 (540)
Medication cost for pneumonic diseases‖
Year 1 7 (49) 27 (181) 16 (106) 43 (205)
Year 2 10 (49) 50 (334) 12 (52) 33 (92)
Year 3 29 (151) 82 (389) 7 (18) 47 (110)
Antimicrobials cost¶
Year 1 50 (124) 68 (260) 38 (82) 111 (239)
Year 2 91 (207) 114 (364) 97 (172) 178 (351)
Year 3 151 (282) 167 (450) 126 (199) 334 (729)
Antidiabetic medication costs#
Year 1 19 (117) 28 (146) 39 (254) 55 (207)
Year 2 29 (201) 57 (304) 54 (369) 84 (318)
Year 3 21 (220) 70 (338) 46 (232) 148 (435)
ADA ¼ adalimumab; ETN ¼ etanercept; IFX ¼ inﬂiximab; TCZ ¼ tocilizumab; csDMARDs ¼ conventional synthetic
disease-modifying antirheumatic drugs; ATC ¼ Anatomical Therapeutic Chemical.
aETN vs IFX, P o 0.01.
bETN vs ADA, P o 0.01.
cETN vs ADA, P o 0.05.
dETN vs IFX, P o 0.05.
eETN vs TCZ, P o 0.001.
fIFX vs ADA, P o 0.05.
gIFX vs TCZ, P o0.001.
*csDMARDs include actarit, auranoﬁn, salazosulfapyridine, bucillamine, lobenzarit disodium, sodium aurothiomalate,
D-penicillamine, tacrolimus, mizoribine, leﬂunomide, and methotrexate.
†ATC code H02A2 or H02B.
‡ATC code M01A (excluding leﬂunomide) or M02 (excluding prednisolone farnesylate).
§Medical practice cost includes medical consultation fee (chronic painful disease management fee); rheumatology-related tests (auto-
antibody test, immunological test interpretation fee, erythrocyte sedimentation rate); rheumatology-related surgery (synovectomy).
‖ATC code R03.
¶ATC code J01.
#ATC code A10.
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Clinical TherapeuticsThe switching rates (95% CI) at month 36 were
12.5% (7.6%–17.3%) in the ETN group, 27.1%
(19.5%–34.7%) in the IFX group, 31.0% (17.4%–
44.6%) in the ADA group, and 16.7% (2.0%–31.4%)
in the TCZ group. (Figure 5B). From the log-rank test,
the unadjusted switching rate was less with ETN com-
pared with ADA (P ¼ 0.003) and IFX (P ¼ 0.006) and
with TCZ versus ADA (P¼ 0.016). HRs (95%CI) of the
switching rates adjusted for age, sex, and methotrexate
dose versus ETN (reference) were signiﬁcantly greater for
ADA and IFX (2.369 [1.358–4.131] and 1.972 [1.201–
3.238]), and the HR versus ADA (reference) was signiﬁ-
cantly less for TCZ (0.363 [0.147–0.892]) (Table III).Relative Dose Intensity Analysis
The estimated mean initial doses of ETN in the 25-
and 50-mg dose groups were 27.4 and 56.1 mg/wk,
respectively (Figure 6). Estimated mean initial doses
appeared greater than the approved doses due to the
method used for allocating patients into the 2 dosing
categories (eg, patients receiving 17.5–37.5 mg/wk
between months 2 and 3 were assigned to the ETN 25-
mg dose group). Some patients may also have received
5 doses of ETN 50 mg in a 30-day period. The mean
(95% CI) RDIs of the ETN 25 mg, ETN 50 mg, IFX,
ADA, and TCZ groups until discontinuation were 1.02
(0.95–1.10), 0.82 (0.79–0.85), 1.16 (1.12–1.20), 0.95
(0.90–0.99), and 0.96 (0.93–1.00), respectively (Figure 6).DISCUSSION
In this retrospective analysis of data from a Japanese
claims database, the rate of discontinuation of ETN
was the lowest among 3 TNF inhibitors and 1
interleukin-6 receptor inhibitor when used as the
ﬁrst-line biologic treatment. Direct biologic costs and
cumulative medical costs were also lowest with ETN
over all 3 years, despite the self-injection and out-
patient chemotherapy-management fees being the
greatest, which were thought to be offset by the lesser
biologic cost. Administration costs were likely greater
with ETN versus IFX owing to the ways that costs are
recorded; self-injection management or outpatient
chemotherapy premiums are physicians' management
fees, which do not include the administration costs or
transportation costs incurred with IFX administration.
Adherence to treatment has been associated with a
reduction in overall medical costs in RA patients,24
which could help to explain the lesser medical costs1368incurred with ETN use. The main reasons for poor
adherence to TNF inhibitors in RA are lack of efﬁcacy
and AEs,19,25 which implies that ETN is perceived as
relatively efﬁcacious and well-tolerated. Several stud-
ies support greater adherence rates with ETN com-
pared with other TNF inhibitors.25,26
ETN is scored higher than IFX on the LUNDEX
index, which is used for comparing the long-term
efﬁcacy and tolerability of biologic therapies for RA
patients treated in clinical practice, mainly because of
the greater rate of adherence to ETN therapy.21 A
review of the medical records of Japanese patients
enrolled in the Osaka University Biologics for
Rheumatic Diseases registry found that rates of
continuation of TCZ and ETN were greater than
those of IFX and ADA, and that discontinuation due
to lack of efﬁcacy was less in TCZ-treated patients.27
When adjusting for baseline age, sex, and metho-
trexate dose, our Cox proportional hazards model
showed similar results with the previous reports; risk
for discontinuation was signiﬁcantly greater in
patients using ADA and IFX versus ETN.
The risk for drug discontinuation due to AEs was
assessed in a group of patients enrolled in the Registry of
Japanese RA Patients for Long-term Safety database.22
In their Cox proportional hazards model, patients were
signiﬁcantly more likely to discontinue treatment with
IFX (HR [95% CI] ¼ 1.69 [1.14–2.51]) or TCZ (1.98
[1.04–3.76]) due to AEs than they were with ETN.22
The risk for discontinuation due to AEs was also
signiﬁcantly greater in patients with increasing age by
decade (HR [95% CI] ¼ 1.64 [1.38–1.97]) and with the
use of Z3 previous conventional synthetic disease-
modifying antirheumatic drugs (1.86 [1.30–2.67]).22
In our Cox proportional hazards model, among the
variables included, the risk for discontinuation was
signiﬁcantly less for increasing methotrexate dose by 1
mg (HR [95% CI] ¼ 0.969 [0.943–0.997]). The risk
for discontinuation was signiﬁcantly less for age Z40
years, age o60 years (0.661 [0.504–0.867]), and age
Z60 years (0.591 [0.395–0.885]) compared with age
o40 years. The greater risk for discontinuation in
younger patients was inconsistent with ﬁndings from
previous reports,22,28 possibly owing to the small
number of patients aged 460 years and no data for
those aged 475 years in the JMDC database. There
may also be an undetected cofounding factor for
nonadherence to biologics treatment in patients aged
o40 years in this JMDC population. In a study of theVolume 38 Number 6
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Figure 5. A, Biologic discontinuation event rate. B, Switching event rate. Discontinuation and switching rates
in each group were estimated using Kaplan-Meier survival analysis. A discontinuation occurred when a
drug was not prescribed for an administration interval longer than can be explained by the dosing
schedule for each biologic (etanercept, 4 months; infliximab, 5 months; adalimumab, 4 months;
tocilizumab, 4 months) or when one biologic was switched to another. Pairwise comparisons of
discontinuation rates between treatment groups were analyzed by log-rank (Mantel-Cox) tests.
A switch occurred when the first biologic prescribed was changed to an alternative biologic agent.
N. Sugiyama et al.persistent use of glaucoma therapy in Japanese
patients in the JMDC database, younger age was also
associated with reduced persistence with treatment.29June 2016It has been shown that health care resource
utilization costs, mainly attributed to RA-related
hospitalizations, are reduced when patients with RA1369
Table III. Cox proportional hazards regression
results for biologic discontinuation*
event rate and switching† event rate.
Variable
Hazard Ratio
(95% CI)
End point ¼ discontinuation
rate
ADA vs ETN 1.618 (1.132–2.313)
IFX vs ETN 1.534 (1.138–2.068)
TCZ vs ETN 1.153 (0.734–1.812
IFX vs ADA 0.948 (0.670–1.343)
TCZ vs ADA 0.713 (0.438–1.159)
IFX vs TCZ 1.331 (0.851–2.080)
Age Z40–o60 y vs
age o40 y
0.661 (0.504–0.867)
Age 60 y vs
age o40 y
0.591 (0.395–0.885)
Male vs female 0.860 (0.634–1.167)
MTX dose (increase
by 1 mg)
0.969 (0.943–0.997)
End point ¼ switching rate
ADA vs ETN 2.369 (1.358–4.131)
IFX vs ETN 1.972 (1.201–3.238)
TCZ vs ETN 0.859 (0.352–2.094)
IFX vs ADA 0.833 (0.500–1.386)
TCZ vs ADA 0.363 (0.147–0.892)
IFX vs TCZ 2.296 (0.966–5.455)
Age Z40–o60 y vs
age o40 y
0.732 (0.472–1.137)
Age 60 y vs
age o40 y
0.653 (0.342–1.249)
Male vs female 0.885 (0.545–1.437)
MTX dose (increase
by 1 mg)
0.996 (0.954–1.039)
ADA ¼ adalimumab; ETN ¼ etanercept; IFX ¼ inﬂiximab;
MTX ¼ methotrexate; TCZ ¼ tocilizumab.
*An event was considered a discontinuation when the drug
was not prescribed for an administration interval longer
than can be explained by the dosing schedule for each
biologic (etanercept, 4 months; inﬂiximab, 5 months;
adalimumab, 4 months; tocilizumab, 4 months) or when
one biologic was switched to another.
†An event was considered a switch when the ﬁrst bio-
logic prescribed was changed to an alternative biologic
agent.
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1370achieve sustained remission.30 Sustained remission
and improved cost-effectiveness are better achieved
when patients adhere to the treatment-to-target strat-
egy.31,32 In another study, while it was reported that
treatment persistence was greater with IFX plus
methotrexate compared with ADA plus methotrexate
or ETN plus methotrexate, lesser nonpharmacy costs
were associated with high persistence.33 We observed
that discontinuation rates were greatest with ADA,
but that direct medical costs were greatest with
IFX, suggesting that nonadherence is only one of the
drivers of increased costs.
The cost of IFX treatment could be greater due to
dose escalation in the early stages of treatment. In the
literature, greater rates of dose escalation have been
associated with higher related costs.34–36 In this study,
RDI analysis of IFX until discontinuation showed the
actual dose to be 1.16-fold greater than the expected
dose, which supports the practice of dose escalation.
Systematic literature reviews and analyses of claims
data have revealed that dose escalation is more
common with IFX and ADA and less frequent with
ETN.34,35,37,38 It is important to acknowledge that the
approval of dose escalation in the product labeling for
IFX39 and ADA40 could result in more frequent dose
escalation compared with ETN. However, if pre-
scribers were more likely to avoid dose escalation
with ETN in cases of insufﬁcient efﬁcacy, one might
expect to observe greater rates of discontinuation or
switching with ETN. This was not the case in our
study, in which rates of discontinuation and switching
when ETN was used as the ﬁrst-line biologic were the
lowest. In the Cox proportional hazards model,
adjusted HRs for switching were signiﬁcantly greater
for ADA and IFX versus ETN, and the risk for
switching from TCZ was signiﬁcantly less versus
ADA.
Dose reduction while maintaining efﬁcacy has also
been shown for ETN in the PRESERVE (Mainte-
nance, Reduction, or Withdrawal of Etanercept After
Treatment With Etanercept and Methotrexate in
Patients With Moderate Rheumatoid Arthritis),41
PRIZE (Sustained Remission With Etanercept
Tapering in Early Rheumatoid Arthritis),42 DOSERA
(Full Dose, Reduced Dose or Discontinuation of
Etanercept in Rheumatoid Arthritis)43 clinical studies
but has not been fully conﬁrmed in Japanese clinicalVolume 38 Number 6
Mean RDI (95% CI)
Dose decrease Dose increase
Estimated initial dose
27.4 mg/week
56.1 mg/week
246.9 mg/2 months
46.5 mg/2 weeks
439.9 mg/month
1.5
Etanercept 25 mg/week (n = 101)
Etanercept 50 mg/week (n = 164)
Infliximab (n = 217)
Adalimumab (n = 130)
Tocilizumab (n = 85)
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Figure 6. Mean relative dose intensity (RDI) for each drug until discontinuation. RDI ¼ (Actual cumulative
dose)/(Initial dose  Period until discontinuation).
N. Sugiyama et al.settings. Here, we demonstrate that the RDI of ETN
50 mg was 0.82-fold less than that of the
recommended highest dose, yet drug retention was
the greatest of all of the biologics. Together with low
discontinuation and switching rates, this ﬁnding
suggests maintained efﬁcacy at a reduced dose. It is
also important to acknowledge that low-dose ETN
(25 mg) is often prescribed as the ﬁrst-line dose in
Japan, to reduce economic and/or AE burden and/or
to compensate for the generally lesser weight of
Japanese individuals versus those from Western coun-
tries.44 The tendency to reduce the dose of ETN
during treatment, or to initially prescribe a lower
dose, could also contribute to the lesser cost of ETN
observed compared with other drugs.
Effective disease control achieved through intensive
escalations of biologics in patients with nonresponse
to conventional synthetic disease-modifying antirheu-
matic drugs is thought to be a justiﬁed use of societal
resources.15 Proactive control of disease activity has
also been associated with lesser medical and
nonmedical costs in a large-scale Japanese cohort.45
However, rather than escalating the dose, it may be
more cost-effective to switch to a biologic with a
different mechanism of action if TNF inhibitors
have failed.15,46,47 An analysis from the Netherlands
demonstrated that starting patients on biologics with a
lesser risk for developing neutralizing antibodies
(eg, ETN rather than ADA or IFX) increased drugJune 2016retention and cost-effectiveness in the treatment of
RA.48 This ﬁnding is in agreement with those from
this study, which showed that cumulative biologic
costs and total costs were lowest when ETN was used
as the ﬁrst-line biologic agent but greatest when IFX
and ADA were used ﬁrst.
It is recognized that economic approaches differ
among countries, so cost-effectiveness analyses cannot
be generalized.49,50 However, annual costs per treated
patient with RA in a multistate Medicaid population
were less with ETN ($18,466) than with ADA
($20,983) or IFX ($26,516).51 ETN was also
associated with the lowest drug and outpatient costs
compared with IFX and ADA in a retrospective study
of health plan costs.52 In an analysis of data from
45000 patients with RA from the Optum Research
Database, ETN was the most effective and had the
lowest biologic cost per effectively treated patient with
RA, compared with ADA, IFX, abatacept, and
golimumab.53 Some studies have suggested that TCZ
may be more cost-effective than ADA monotherapy54
and ADA or ETN when used in combination with
methotrexate.55 Cumulative medical costs of TCZ
were similar to those of ADA but were greater than
those of ETN in our study; however, further research
is needed to determine the cost-effectiveness of the
TCZ therapeutic strategy in this population.
This study may be limited by the retrospective
nature of the analysis and the lack of randomization1371
Clinical Therapeuticsof patients to treatment groups, leading to channeling
bias. Also, ﬁrst-line biologic use in biologic-naive
patients was deﬁned as that in patients who had no
record of a biologic prescription in the 3 months
before the ﬁrst known prescription of the biologic in
the JMDC database. It is therefore possible that some
of the patients included in the study were actually
prevalent users of biologics. The study is, however,
representative of the prescribing situation in clinical
practice in Japan. Efﬁcacy data were also not available
from the JDMC. While drug discontinuation rates can
be used as a surrogate for therapeutic response, it
should be considered that several other factors, such
as drug tolerability, availability, and cost, may affect
biologic-discontinuation rates. Assessments of clinical
disease activity in each treatment group would inform
a more thorough cost-effectiveness analysis. The ADA
and IFX groups included more males (23.8%–29.8%)
and fewer females (76.2%–70.2%) compared with the
ETN group (19.6% vs 80.4%), which could have
inﬂuenced therapeutic response56 and adherence to
treatment.57 The JMDC database includes relatively
few elderly individuals as a consequence of a separate
medical insurance system for those aged475 years in
Japan. In addition, JMDC includes beneﬁciaries
covered by an employee's health insurance system,
so most beneﬁciaries are those of working age or
their families. This analysis was therefore limited to
patients agedo75 years, which may bias our ﬁndings.
Medical costs may be expected to be greater in the
elderly, so our data should be interpreted with this in
mind. Finally, this study cannot estimate the total cost
of RA because information on indirect costs was not
included, and direct RA-related costs (excluding those
of comorbidities) could not be estimated from the
JMDC data.CONCLUSIONS
Our retrospective analysis suggests that in Japan, if
ETN is used as the ﬁrst-line biologic, direct biologic
and direct medical costs are less than those of other
biologics, in part owing to the high therapeutic
retentiveness of ETN. Low drug costs could be
partially explained by the practice of ETN dose
reduction and the preferred use of low-dose ETN in
patients in Japan. We anticipate that our ﬁndings will
help to guide prescribing decisions as well as support
payers and/or government decision making with1372regard to medical costs. However, further research
or prospective clinical studies are necessary to conﬁrm
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Figure. S1Longitudinal analysis: N = 764
ETN: n = 276
ETN: n = 227
ETN: n = 158
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ADA: n = 30
ADA: n = 57
ADA: n = 147
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IFX: n = 242
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2-Year cumulative cost analysis: N = 404
3-Year cumulative cost analysis: N = 273
TCZ: n = 40
Exclusion Criteria
Follow-up period <12 months
Follow-up period <24 months
Follow-up period <36 months
Supplemental Figure. Cross-sectional cumulative cost analysis. The 1-, 2-, and 3-year cumulative cost for
patients with rheumatoid arthritis followed up for 41, 42, or 43 years, respectively,
after the initial prescription of biologics. Data from treatment groups were compared
with those from a group of biologic-naive patients. ADA ¼ adalimumab; ETN ¼
etanercept; IFX ¼ infliximab; TCZ ¼ tocilizumab.1375.e1 Volume 38 Number 6
